Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
Date:6/17/2011

ructions, this side effect may be reduced or it may go away over time.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Some medications interact with RISPERDAL®. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid alcohol while taking RISPERDAL®.

Inform your healthcare professional if you are pregnant or if you are planning to get pregnant while taking RISPERDAL®. Do not breast-feed if you are taking RISPERDAL®.

RISPERDAL® may affect your driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL® may affect alertness and motor skills; use caution until the effect of RISPERDAL is known.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and gove
'/>"/>

SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
2. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
5. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
6. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
7. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
8. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
9. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
10. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 29, 2011 Professional and Trade Relations groups play ... to professional, payer and patient groups. However, today,s restrictive ... PTR activities - thus creating pressure on PTR groups ... optimize their impact.   Recognizing changing needs ...
... April 29, 2011 Phil Hagerman, president and CEO of ... Leader & Innovator of the Year. The award ... which co-sponsors the annual award along with Grant Thornton LLP, ... and Technology Report. Hagerman was chosen from among 45 nominees ...
Cached Medicine Technology:Professional Relations Excellence Outlined in New Best Practices, LLC Report 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 3
(Date:7/30/2015)... & Caicos Islands, BWI (PRWEB) , ... July 31, 2015 , ... The Venetian on ... for fall, 2015. Guests who stay at the Venetian will save 40% on their ... The fall months are always quiet in the Turks & Caicos, providing a chance to ...
(Date:7/30/2015)... ... 30, 2015 , ... The Clinical Data Interchange Standards Consortium ... announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis ... . These three Therapeutic Area (TA) standards were developed per the CDISC global, ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will ... site. As discussed in a June 8, 2015 article published by Nasdaq , ... have been caused by its computer-driven cars, which such industry players as Tesla CEO ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2
... patients would bear the brunt of a Government proposal to ... ,This plan would very likely push up the ... to pay for their medication facing a greater financial burden, ... it ensures that Australians are able to access the ...
... avian influenza since 2005, state media said Friday. ... a 29-year-old man has been infected with the deadly H5N1 ... to Vietnam News Agency. ,The man, from Vinh ... from high fever and breathing difficulties on May 10. He ...
... improve global public health, Weill Cornell Medical College students ... the World Health Organization's (WHO) list of essential ... to choose which high-priority drugs should be supplied to ... chapter of Universities Allied for Essential Medicines (UAEM) answered ...
... that they have identified a gene that needs to be ... ,The gene detected by the researchers ... of the well-known breast cancer gene BRCA1. ,The ... of the University of Pennsylvania and the Dana-Farber Cancer Institute, ...
... that appetite-regulating peptides leptin and ghrelin influence alcohol cravings ... powerful urge to drink, is an important contributor to ... Otto Lesch of the University of Vienna has divided ... that refers to people with heavy alcohol withdrawals who ...
... has opened one of the few clinics in the ... Down Syndrome. Because of improvements in diagnosis, treatment ... patients are now routinely living into adulthood, and have ... of the population. ,Childrens hospitals, pediatricians and our ...
Cached Medicine News:Health News:Medical College Students Help Change Global Health Policy 2Health News:Scientists Identify New Breast Cancer Gene 2Health News:Appetite-regulating Peptides Influence Alcohol Cravings 2Health News:Adult Down Syndrome Clinic Opened at UAB 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: